Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort

Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort

Abstract Background/purpose Studies have demonstrated that rheumatoid arthritis (RA) patients who achieve low disease activity or remission are able to taper biological disease-modifying antirheumatic drugs (bDMARDs). The aim of this study was to evaluate the proportion of patients in whom bDMARDs c...

Full description

Bibliographic Details
Main Authors: Stéphanie Dierckx, Tatiana Sokolova, Bernard R. Lauwerys, Aleksandra Avramovska, Laurent Meric de Bellefon, Adrien Nzeusseu Toukap, Maria Stoenoiu, Frédéric A. Houssiau, Patrick Durez
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
bioDMARDs
Remission
Dose tapering
Online Access:http://link.springer.com/article/10.1186/s13075-020-02165-4

Internet

http://link.springer.com/article/10.1186/s13075-020-02165-4

Similar Items